Antidepressants in clinical practice: Limitations of assessment methods and drug response

Human Psychopharmacology

Volumn 16, Issue 1, 2001, Pages 105-114

  Dinan, Timothyg ^a  

^a ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

Author keywords

Antidepressants; Diagnostic heterogeneity functional brain imaging; Efficacy; Major Depressive Disorder

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; IMIPRAMINE; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITOR; PAROXETINE; PHENELZINE; SEROTONIN; SEROTONIN RECEPTOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

ADULT; ARTICLE; BRAIN FUNCTION; CLINICAL PRACTICE; CLINICAL TRIAL; COGNITIVE THERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA BASE; DEPRESSION; DRUG EFFICACY; DRUG RESPONSE; FEMALE; HUMAN; IMAGING; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TIME; TREATMENT OUTCOME;

EID: 0035107045     PISSN: 08856222     EISSN: None     Source Type: Journal    
DOI: 10.1002/hup.189     Document Type: Article

References (48)

1. Social functioning and residual symptomatology among outpatients who responded to treatment and recovered from major depression
2. An inventory for measuring depression
3. Serotonin and drug-induced therapeutic responses in major depression, obsessive-compulsive and panic disorders
4. Fenfluramine releases serotonin from human brain nerve endings by a dual mechanism
5. The dexamethasone suppression test for melancholia
6. A double-blind comparison of velafaxine and fluoxetine in patients hospitalized for major depression and melancholia
7. Randomized, double-blind comparison of venlafaxine and fluoxetine in outpatients with major depression
8. The enduring psychosocial consequences of mania and depression
9. Citalopram: Clinical effect profile in comparison with clomipramine. A controlled multicenter study
10. Paroxetine: A selective serotonin reuptake inhibitor showing better tolerance, but weaker antidepressant effect than clomipramine in a controlled multicenter study
11. Moclobemide: A reversible MAO-A-inhibitor showing weaker antidepressant effect than clomipramine in a controlled multicenter study
12. Measuring outcomes
13. Do noradrenaline and serotonin differentially affect social motivation and behaviour?
14. Quality of life enjoyment and satisfaction questionnaire: A new measure
15. 18F]FDG PET reveals a consistent pattern of differences in brain metabolism in depressed patients and healthy controls
16. Role of 5-HT in stress, anxiety and depression
17. A rating scale for depression
18. Efficacy of SSRIs and newer antidepressants in severe depression: Comparison with TCAs
19. Treatment of atypical depression with cognitive therapy or phenelzine: A double-blind, placebo-controlled trial
20. Pharmacological treatment of severely depressed patients: A meta-analysis comparing efficacy of mirtazapine and amitriptyline
21. Disorders of eating
22. Imipramine and social-vocational adjustment in chronic depression
23. The effects of venlafaxine on social activity level in depressed outpatients
24. Serotonin receptors and their function in sleep, anxiety disorders and depression
25. Phenelzine vs imipramine in atypical depression: A preliminary report
26. Demonstration in vivo of reduced serotonin responsivity in the brain of untreated depressed patients
27. Reciprocal limbic-cortical function and negative mood: Converging PET findings in depression and normal sadness
28. 18F]setoperone PET imaging study
29. 2O PET response to intravenous d-fenfluramine
30. New developments in the treatment of depression
31. Pharmacological effects of paroxetine after repeated administration to animals
32. Fluoxetine versus phenelzine in atypical depression
33. Residual symptoms after partial remission: An important outcome in depression
34. Pharmacotherapy for major depression with melancholic features: Relative efficacy of tricyclic versus selective serotonin reuptake inhibitor anti-depressants
35. Venlafaxine and paroxetine in treatment-resistant depression
36. Use of pattern analysis to identify true drug response. A replication
37. Columbia atypical depression. A subgroup of depressives with better response to MAOI than to tricyclic antidepressants or placebo
38. Estimating causal effects from large data sets using propensity scores
39. Delayed onset of action of antidepressant drugs? Survey of results of Zurich meta-analyses
40. Relapse after cognitive behavior therapy of depression: Potential implications for longer courses of treatment
41. Monoamines and abnormal behavior. A multi-aminergic perspective
42. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection
43. The functioning and well-being of depressed patients. Results from the Medical Outcomes Study
44. A structured interview guide for the Hamilton Depression Rating Scale
45. Decrease in brain serotonin 2 receptor binding in patients with major depression following desipramine treatment: A positron emission tomography study with fluorine-18-labeled setoperone